Differential effects of histone acetyltransferase GCN5 or PCAF knockdown on urothelial carcinoma cells

International Journal of Molecular Sciences

Volumn 18, Issue 7, 2017, Pages

  Koutsogiannouli, Evangelia A ^a   Wagner, Nicholas ^a   Hader, Christiane ^a   Pinkerneil, Maria ^a   Hoffmann, Michèle J ^a   Schulz, Wolfgang A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bladder cancer; c MYC; CBP; Epigenetic drugs; GCN5; Histone acetyltransferases; MDM2; p300; PCAF; Urothelial carcinoma

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 3; CASPASE 7; E1A ASSOCIATED P300 PROTEIN; HISTONE ACETYLTRANSFERASE GCN5; HISTONE ACETYLTRANSFERASE PCAF; MEMBRANE PROTEIN; MESSENGER RNA; MYC PROTEIN; MYST3 PROTEIN; MYST4 PROTEIN; PROTEIN MDM2; SMALL INTERFERING RNA; TRRAP PROTEIN; UNCLASSIFIED DRUG; P300-CBP-ASSOCIATED FACTOR; PROTEIN BINDING; TUMOR MARKER;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL VIABILITY ASSAY; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SENESCENCE; TRANSITIONAL CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA CELL LINE; UPREGULATION; WESTERN BLOTTING; CARCINOMA; CELL AGING; CELL SURVIVAL; GENE EXPRESSION; GENE KNOCKDOWN; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; URETHRA TUMOR;

APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; CELLULAR SENESCENCE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; P300-CBP TRANSCRIPTION FACTORS; PROTEIN BINDING; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; URETHRAL NEOPLASMS;

EID: 85021894078     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18071449     Document Type: Article

References (37)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 2017, 67, 7–30.
2. Kamat, A.M.; Hahn, N.M.; Efstathiou, J.A.; Lerner, S.P.; Malmstrom, P.U.; Choi, W.; Guo, C.C.; Lotan, Y.; Kassouf, W. Bladder cancer. Lancet 2016, 388, 2796–2810.
3. Volanis, D.; Papadopoulos, G.; Doumas, K.; Gkialas, I.; Delakas, D. Molecular mechanisms in urinary bladder carcinogenesis. J. BUON 2011, 16, 589–601.
4. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507, 315–322.
5. Gui, Y.; Guo, G.; Huang, Y.; Hu, X.; Tang, A.; Gao, S.; Wu, R.; Chen, C.; Li, X.; Zhou, L., et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 2011, 43, 875–878.
6. Yang, X.; Yu, W.; Shi, L.; Sun, L.; Liang, J.; Yi, X.; Li, Q.; Zhang, Y.; Yang, F.; Han, X., et al. HAT4, a golgi apparatus-anchored B-type histone acetyltransferase, acetylates free histone H4 and facilitates chromatin assembly. Mol. Cell 2011, 44, 39–50.
7. Nagy, Z.; Tora, L. Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 2007, 26, 5341–5357.
8. Wang, Y.L.; Faiola, F.; Xu, M.; Pan, S.; Martinez, E. Human ATAC is a GCN5/PCAF-containing acetylase complex with a novel NC2-like histone fold module that interacts with the TATA-binding protein. J. Biol. Chem. 2008, 283, 33808–33815.
9. Chen, L.; Wei, T.; Si, X.; Wang, Q.; Li, Y.; Leng, Y.; Deng, A.; Chen, J.; Wang, G.; Zhu, S., et al. Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, Cyclin D1, and Cyclin E1 expression. J. Biol. Chem. 2013, 288, 14510–14521.
10. Liu, K.; Zhang, Q.; Lan, H.; Wang, L.; Mou, P.; Shao, W.; Liu, D.; Yang, W.; Lin, Z.; Lin, Q., et al. GCN5 potentiates glioma proliferation and invasion via STAT3 and Akt signaling pathways. Int. J. Mol. Sci. 2015, 16, 21897–21910.
11. Yin, Y.W.; Jin, H.J.; Zhao, W.; Gao, B.; Fang, J.; Wei, J.; Zhang, D.D.; Zhang, J.; Fang, D. The histone acetyltransferase GCN5 expression is elevated and regulated by c-MYC and E2F1 transcription factors in human colon cancer. Gene Expr. 2015, 16, 187–196.
12. Majaz, S.; Tong, Z.; Peng, K.; Wang, W.; Ren, W.; Li, M.; Liu, K.; Mo, P.; Li, W.; Yu, C. Histone acetyl transferase GCN5 promotes human hepatocellular carcinoma progression by enhancing AIB1 expression. Cell Biosci. 2016, 6, 47.
13. Kenneth, N.S.; Ramsbottom, B.A.; Gomez-Roman, N.; Marshall, L.; Cole, P.A.; White, R.J. TRRAP and GCN5 are used by c-MYC to activate RNA polymerase III transcription. Proc. Natl. Acad. Sci. USA 2007, 104, 14917–14922.
14. Liu, X.; Vorontchikhina, M.; Wang, Y.L.; Faiola, F.; Martinez, E. STAGA recruits mediator to the MYC oncoprotein to stimulate transcription and cell proliferation. Mol. Cell Biol. 2008, 28, 108–121.
15. Zhang, N.; Ichikawa, W.; Faiola, F.; Lo, S.Y.; Liu, X.; Martinez, E. MYC interacts with the human STAGA coactivator complex via multivalent contacts with the GCN5 and TRRAP subunits. Biochim. Biophys. Acta 2014, 1839, 395–405.
16. Malatesta, M.; Steinhauer, C.; Mohammad, F.; Pandey, D.P.; Squatrito, M.; Helin, K. Histone acetyltransferase PCAF is required for Hedgehog-Gli-dependent transcription and cancer cell proliferation. Cancer Res. 2013, 73, 6323–6333.
17. Zheng, X.; Gai, X.; Ding, F.; Lu, Z.; Tu, K.; Yao, Y.; Liu, Q. Histone acetyltransferase PCAF up-regulated cell apoptosis in hepatocellular carcinoma via acetylating histone H4 and inactivating Akt signaling. Mol. Cancer 2013, 12, 96.
18. Gai, X.; Tu, K.; Li, C.; Lu, Z.; Roberts, L.R.; Zheng, X. Histone acetyltransferase PCAF accelerates apoptosis by repressing a GLI1/BCL2/BAX axis in hepatocellular carcinoma. Cell Death Dis. 2015, 6, e1712.
19. Zhang, S.; Sun, G.; Wang, Z.; Wan, Y.; Guo, J.; Shi, L. PCAF-mediated Akt1 acetylation enhances the proliferation of human glioblastoma cells. Tumour. Biol. 2015, 36, 1455–1462.
20. Fei, H.J.; Zu, L.D.; Wu, J.; Jiang, X.S.; Wang, J.L.; Chin, Y.E.; Fu, G.H. PCAF acts as a gastric cancer suppressor through a novel PCAF-p16-CDK4 axis. Am. J. Cancer Res. 2016, 6, 2772–2786.
21. Wan, J.; Xu, W.; Zhan, J.; Ma, J.; Li, X.; Xie, Y.; Wang, J.; Zhu, W.G.; Luo, J.; Zhang, H. PCAF-mediated acetylation of transcriptional factor HOXB9 suppresses lung adenocarcinoma progression by targeting oncogenic protein JMJD6. Nucleic Acids Res. 2016, 44, 10662–10675.
22. Linares, L.K.; Kiernan, R.; Triboulet, R.; Chable-Bessia, C.; Latreille, D.; Cuvier, O.; Lacroix, M.; Le Cam, L.; Coux, O.; Benkirane, M. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat. Cell Biol. 2007, 9, 331–338.
23. Jin, Y.; Zeng, S.X.; Dai, M.S.; Yang, X.J.; Lu, H. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J. Biol. Chem. 2002, 277, 30838–30843.
24. Jin, Y.; Zeng, S.X.; Lee, H.; Lu, H. MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation. J. Biol. Chem. 2004, 279, 20035–20043.
25. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E., et al. The cBIO cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401–404.
26. Forbes, S.A.; Beare, D.; Gunasekaran, P.; Leung, K.; Bindal, N.; Boutselakis, H.; Ding, M.; Bamford, S.; Cole, C.; Ward, S., et al. Cosmic: Exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015, 43, D805–D811.
27. Pinkerneil, M.; Hoffmann, M.J.; Deenen, R.; Kohrer, K.; Arent, T.; Schulz, W.A.; Niegisch, G. Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms. Mol. Cancer Ther. 2016, 15, 299–312.
28. Van der Meulen, J.; Sanghvi, V.; Mavrakis, K.; Durinck, K.; Fang, F.; Matthijssens, F.; Rondou, P.; Rosen, M.; Pieters, T.; Vandenberghe, P., et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood 2015, 125, 13–21.
29. Love, I.M.; Sekaric, P.; Shi, D.; Grossman, S.R.; Androphy, E.J. The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3. Cell Cycle 2012, 11, 2458–2466.
30. Kikuchi, H.; Takami, Y.; Nakayama, T. GCN5: A supervisor in all-inclusive control of vertebrate cell cycle progression through transcription regulation of various cell cycle-related genes. Gene 2005, 347, 83–97.
31. Schulz, W.A. Understanding urothelial carcinoma through cancer pathways. Int. J. Cancer 2006, 119, 1513–1518.
32. Helming, K.C.; Wang, X.; Wilson, B.G.; Vazquez, F.; Haswell, J.R.; Manchester, H.E.; Kim, Y.; Kryukov, G.V.; Ghandi, M.; Aguirre, A.J., et al. ARID1b is a specific vulnerability in ARID1a-mutant cancers. Nat. Med. 2014, 20, 251–254.
33. Ogiwara, H.; Sasaki, M.; Mitachi, T.; Oike, T.; Higuchi, S.; Tominaga, Y.; Kohno, T. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. Cancer Discov. 2016, 6, 430–445.
34. Simon, R.P.; Robaa, D.; Alhalabi, Z.; Sippl, W.; Jung, M. Katching-up on small molecule modulators of lysine acetyltransferases. J. Med. Chem. 2016, 59, 1249–1270.
35. Richters, A.; Koehler, A.N. Epigenetic modulation using small molecules-targeting histone acetyltransferases in disease. Curr. Med. Chem. 2017, doi:10.2174/0929867324666170223153115.
36. Gajer, J.M.; Furdas, S.D.; Grunder, A.; Gothwal, M.; Heinicke, U.; Keller, K.; Colland, F.; Fulda, S.; Pahl, H.L.; Fichtner, I., et al. Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo. Oncogenesis 2015, 4, e137.
37. Swiatkowski, S.; Seifert, H.H.; Steinhoff, C.; Prior, A.; Thievessen, I.; Schliess, F.; Schulz, W.A. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp. Cell Res. 2003, 282, 48–57.